Racquel Wells1, Mahboob Rahman2,3. 1. Department of Medicine, University Hospitals Cleveland Medical Center, Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, 11100 Euclid Ave., Cleveland, OH, 44106, USA. 2. Department of Medicine, University Hospitals Cleveland Medical Center, Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, 11100 Euclid Ave., Cleveland, OH, 44106, USA. Mahboob.Rahman@uhhospitals.org. 3. Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, 11100 Euclid Ave., Cleveland, OH, 44106, USA. Mahboob.Rahman@uhhospitals.org.
Abstract
PURPOSE OF REVIEW: To review the impact of the Systolic Blood Pressure Interventional Trial (SPRINT) on renal function and chronic kidney disease. RECENT FINDINGS: Hypertension is a risk factor for cardiovascular and kidney outcomes in patients with chronic kidney disease (CKD). The benefits of intensive blood pressure lowering in the CKD population in previous studies are unclear. The SPRINT compared standard (< 140 mmHg) and intensive (< 120 mmHg) blood pressure management in nondiabetic patients with high risk of cardiovascular disease. In the subgroup of patients with CKD, the most important finding was that intensive blood pressure lowering is associated with lower risk of cardiovascular disease and mortality. Other than lower levels of albuminuria, there was no benefit on clinical kidney outcomes with the intensive treatment group. The risk of incident CKD and episodes of acute kidney injury was higher in patients in the intensive treatment group, though most patients with acute kidney injury recovered kidney function. While the benefit of intensive blood pressure lowering on cardiovascular events and mortality with intensive blood pressure lowering is clear in patients with CKD, longer term follow-up may be needed to fully understand the effect on kidney function.
PURPOSE OF REVIEW: To review the impact of the Systolic Blood Pressure Interventional Trial (SPRINT) on renal function and chronic kidney disease. RECENT FINDINGS:Hypertension is a risk factor for cardiovascular and kidney outcomes in patients with chronic kidney disease (CKD). The benefits of intensive blood pressure lowering in the CKD population in previous studies are unclear. The SPRINT compared standard (< 140 mmHg) and intensive (< 120 mmHg) blood pressure management in nondiabeticpatients with high risk of cardiovascular disease. In the subgroup of patients with CKD, the most important finding was that intensive blood pressure lowering is associated with lower risk of cardiovascular disease and mortality. Other than lower levels of albuminuria, there was no benefit on clinical kidney outcomes with the intensive treatment group. The risk of incident CKD and episodes of acute kidney injury was higher in patients in the intensive treatment group, though most patients with acute kidney injury recovered kidney function. While the benefit of intensive blood pressure lowering on cardiovascular events and mortality with intensive blood pressure lowering is clear in patients with CKD, longer term follow-up may be needed to fully understand the effect on kidney function.
Authors: Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak Journal: Science Date: 2010-07-15 Impact factor: 47.728
Authors: Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton Journal: Clin Trials Date: 2014-06-05 Impact factor: 2.486
Authors: Daniel E Weiner; Sarah A Gaussoin; John Nord; Alexander P Auchus; Gordon J Chelune; Michel Chonchol; Laura Coker; William E Haley; Anthony A Killeen; Paul L Kimmel; Alan J Lerner; Suzanne Oparil; Mohammad G Saklayen; Yelena M Slinin; Clinton B Wright; Jeff D Williamson; Manjula Kurella Tamura Journal: Am J Kidney Dis Date: 2017-06-09 Impact factor: 8.860
Authors: Michael V Rocco; Kaycee M Sink; Laura C Lovato; Dawn F Wolfgram; Thomas B Wiegmann; Barry M Wall; Kausik Umanath; Frederic Rahbari-Oskoui; Anna C Porter; Roberto Pisoni; Cora E Lewis; Julia B Lewis; James P Lash; Lois A Katz; Amret T Hawfield; William E Haley; Barry I Freedman; Jamie P Dwyer; Paul E Drawz; Mirela Dobre; Alfred K Cheung; Ruth C Campbell; Udayan Bhatt; Srinivasan Beddhu; Paul L Kimmel; David M Reboussin; Glenn M Chertow Journal: Am J Kidney Dis Date: 2017-11-20 Impact factor: 8.860
Authors: Alfred K Cheung; Mahboob Rahman; David M Reboussin; Timothy E Craven; Tom Greene; Paul L Kimmel; William C Cushman; Amret T Hawfield; Karen C Johnson; Cora E Lewis; Suzanne Oparil; Michael V Rocco; Kaycee M Sink; Paul K Whelton; Jackson T Wright; Jan Basile; Srinivasan Beddhu; Udayan Bhatt; Tara I Chang; Glenn M Chertow; Michel Chonchol; Barry I Freedman; William Haley; Joachim H Ix; Lois A Katz; Anthony A Killeen; Vasilios Papademetriou; Ana C Ricardo; Karen Servilla; Barry Wall; Dawn Wolfgram; Jerry Yee Journal: J Am Soc Nephrol Date: 2017-06-22 Impact factor: 10.121
Authors: Carl D Langefeld; Jasmin Divers; Nicholas M Pajewski; Amret T Hawfield; David M Reboussin; Diane E Bild; George A Kaysen; Paul L Kimmel; Dominic S Raj; Ana C Ricardo; Jackson T Wright; John R Sedor; Michael V Rocco; Barry I Freedman Journal: Kidney Int Date: 2014-07-16 Impact factor: 10.612
Authors: Barry I Freedman; Michael V Rocco; Jeffrey T Bates; Michel Chonchol; Amret T Hawfield; James P Lash; Vasilios Papademetriou; John R Sedor; Karen Servilla; Paul L Kimmel; Barry M Wall; Nicholas M Pajewski Journal: Kidney Int Rep Date: 2017-03-31